[P25-9] P25-9: Oncologic drugs (1)

[P25-9-1] Dried plasma spot analysis for gefitinib, erlotinib, afatinib and osimertinib using high performance liquid chromatography tandem mass spectrometry

Reiko Ando Makihara¹, Makoto Maeda², Kota Itahashi³, Yasushi Goto⁴, Shintaro Kanda⁵, Hidehito Horinouchi⁶, Yutaka Fujiwara⁷, Taku Tsukamoto⁸, Hironobu Hashimoto⁹, Tomonobu Ohtsuka¹⁰, Yoshinori Makino¹¹, Noboru Yamamoto¹², Yuichiro Ohe¹³, Hiroyuki Terakado¹⁴ (1.National Cancer Center Hospital, 2.National Cancer Center Hospital, 3.National Cancer Center Hospital, 4.National Cancer Center Hospital, 5.National Cancer Center Hospital, 6.National Cancer Center Hospital, 7.National Cancer Center Hospital, 8.Shimadzu Corporation, 9.National Cancer Center Hospital, 10.National Cancer Center Hospital, 11.National Cancer Center Hospital, 12.National Cancer Center Hospital, 13.National Cancer Center Hospital, 14.National Cancer Center Hospital)

Keywords:DPS, lung cancer, EGFR-TKI, LC-MS/MS